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Up to 15% of the reproductive population is infertile, and 3 to 5% of these cases are caused by uterine
dysfunction. This abnormality generally leads women to consider surrogacy or adoption. Uterine transplanta-
tion, although still experimental, may be an option in these cases. This systematic review will outline the
recommendations, surgical aspects, immunosuppressive drugs and reproductive aspects related to experimental
uterine transplantation in women.
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’ INTRODUCTION
Up to 15% of the reproductive population is infertile, and
3 to 5% of all cases of infertility are caused by uterine dys-
function (1). This abnormality generally leads women to con-
sider surrogacy or adoption. However, in many countries,
such as Japan and Sweden, surrogacy is heavily restricted or
even prohibited. Uterine transplantation, although still experi-
mental, may be an option in these cases (2).
The first pelvic organ transplantation, wich was performed
in the 1960s, involved fallopian tube transplantation for the
treatment of tube-peritoneal infertility, although this techni-
que was only successful in an animal model (3). The first
experiments in uterine transplantation were based on the
premise that vascularization is improved if the uterus is
transplanted in combination with the fallopian tubes. The
first experimental model of uterine transplantation, pub-
lished in 1973, was established in dogs (4,5), although the
immunosuppressive drugs available at the time (cortisone
and azathioprine) were inadequate to prevent rejection. The
development of in vitro fertilization then diminished interest
in fallopian tube transplantation, although infertility caused
by uterine factors remained an issue. In this context, several
animal models were studied, such as mice (6), rats (7), rabbits
(8), sheep (9) and primates (10), predominantly in the early
1970s. The first human uterine transplantation was per-
formed in 2002 in Saudi Arabia but resulted in graft loss and
hysterectomy 3 months after transplantation (11). The second
attempt at uterine transplantation occurred in Turkey in 2011
and resulted in two pregnancies, both ending in miscarriage
(12). The first case with successful childbirth was reported in
September 2014 among nine transplant patients in Gothen-
burg, Sweden (13). The 35-year-old patient had uterine
agenesis, only one kidney and vaginal aplasia (a type of
Rokitansky syndrome) and had received a uterus from a
61-year-old living donor 7 years past menopause. In November
2014, two more patients from the same study gave birth. The
present systematic review will address the recommendations,
surgical implications, immunosuppressive strategies and repro-
ductive aspects related to experimental uterine transplantation
in women.
’ METHODOLOGY
This review of uterine transplantation was conducted
in accordance with the PRISMA guidelines for systematic
reviews (14). Multiple databases were searched, including
Medline (PubMed), LILACS and the Cochrane Database.
There were no restrictions on date, but the study was limited
to English-language publications on human subjects.
The titles and abstracts of identified citations were screened
for relevance by two independent reviewers. The full texts of
‘‘relevant’’ and ‘‘potentially relevant’’ articles were retrieved
and evaluated independently by both reviewers. From each of
the selected studies, the two reviewers independently extrac-
ted data on the year and journal of publication. Disagreements
regarding the extracted data were solved by consensus or
through consultation with a third reviewer. The characteristicsDOI: 10.6061/clinics/2016(11)10
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of the selected articles were summarized and evaluated using
narrative synthesis (Figure 1). The systematic literature analy-
sis was specifically conducted using PubMed, LILACS and
the Cochrane Database. In PubMed, a search for the terms
(‘‘Uterus’’ [Mesh]) AND (‘‘transplantation" [Mesh]) yielded
965 studies, with 534 in human subjects. In LILACS, 6 articles
were found following a search for the terms ‘‘uterus AND
transplantation AND human’’, but they were classified by the
reviewers as irrelevant. Finally, in the Cochrane Database,
17 articles were found following a search for the terms ‘‘uterus
AND transplantation AND human’’, but these articles were
also classified as irrelevant.
The articles that were included describe uterine transplanta-
tion techniques in humans with infertility caused by uterine
dysfunction. Five articles were included in total.
Uterus transplantation
Indications. Uterine transplantation may be recom-
mended for women who wish to conceive who have uterine
malformation or who have undergone previous hysterectomy
due to neoplasm, post-partum hemorrhage, increased uterine
bleeding or intrauterine adherences (Asherman syndrome).
Uterine malformation affects up to 5% of the infertile popula-
tion, with uterine agenesis and uterine hypoplasia being the
most frequent causes. In particular, uterine agenesis affects 1 in
every 4,500 women (15).
Hysterectomies are typically carried out because of
myoma, adenomyosis or post-partum hemorrhage. In the
USA, half of the patients attending a particular program for
surrogacy had undergone hysterectomy. Moreover, malignant
neoplasm of the uterine cervix is the third most common
cancer in women. This cancer was responsible for over 5,000
deaths in 2010 in Brazil (16), and the Brazilian Institute of
Cancer (INCA) estimates that there will be 15,590 new cases in
2015 (17).
Aspects of assisted reproduction
In a Swedish study of ovarian stimulation, a patient
underwent nasal administration of a gonadotropin-releasing
hormone agonist 9 days after high levels of luteinizing
hormone were detected (13).
Follicular development was monitored through serial
ultrasounds and serum estradiol measurements. During the
first cycle of ovulation stimulation, only 150 IU of urinary
gonadotropin was used. During the second and third cycles,
180 IU of recombinant gonadotropin and 225 IU of urinary
gonadotropin were used, respectively. The duration of the
cycles was approximately 11 to 14 days. Ovulation was
triggered with human chorionic gonadotropin (HCG), and
oocyte retrieval was subsequently performed. In the first cycle,
only one egg cell was obtained, and one embryo was frozen.
In the second cycle, 4 embryos were obtained from 9 eggs, and
6 embryos were obtained from 8 eggs in the third cycle. The
first menstruation occurred 43 days after transplantation, and
a single embryo was transferred approximately 12 months
after transplantation, during the natural menstrual cycle, with
ultrasound guidance (13).
Aspects related to gestational and
post-partum periods
The first successful pregnancy lacked complications until
the 31st week of gestation, when the patient presented a clini-
cal condition similar to pre-eclampsia (hypertension, protei-
nuria and headaches). The patient was hospitalized and
submitted to cesarean section due to alteration in fetal
wellbeing. During the pregnancy, the patient took tacrolimus,
azathioprine and prednisolone and presented a single mild
rejection episode in the second month of gestation. The baby
weighed 1775 g and was 40 cm in height at birth and was
hospitalized for 16 days in the ICU. At discharge from the
hospital, the baby weighed 2040 g (13). The two subsequent
births reported occurred without complications (18).
Figure 1 - Literature flow diagram for the searches of the PubMed, LILACS and Cochrane databases.
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Surgical aspects
Donor Surgery - The donor can be living or deceased. The
use of living donors was described by BrännströmM. et al. in
2014 (19). Using an infraumbilical midline incision, the
uterus is dissected and isolated along with the ligaments that
are important to hold it in the right position after implanta-
tion. A bilateral salpingectomy is also performed. The uterine
arteries and veins are carefully dissected and separated from
the ureters. The vagina is sectioned such that enough length
is available for anastomosis in the recipient (10 to 15 mm).
Additionally, the uterine vessel branches are cut along with a
small patch from the iliac vessels, and soon after, the organ is
perfused with preservative solution during the back-table
procedure (20). Deceased donors are typically multiple organ
donors, leading to a large midline incision and thus improved
exposition. As a result, retrieval of the organ can be less
restrictive, bringing more vessels with it (namely, iliac vessels),
which can facilitate vascular reconstruction. The uterus is also
heparinized and perfused with preservative solution before
retrieval.
Recipient Surgery - Access is obtained through a midline
infraumbilical incision. The iliac vessels (internal and external)
are also dissected and isolated. It is important to synchronize
the donor/recipient procedures to minimize cold ischemia
time. Implantation is also different depending on the type of
donor. In both cases, the native uterus is removed if present,
and the space is prepared to receive the new organ (vagina,
fixation points). In living donors, the implantation is as
described by Brännström M. et al. (19), requiring more vessel
anastomosis; in particular, arteries and veins are anastomosed
on both sides (right and left) of the external iliac vessels.
Deceased donation can allow less vessel anastomosis; the
internal iliac vessels can be reconstructed during the back-
table procedure and anastomosed via one artery (aorta or iliac
extern) and one vein (cava or iliac extern). The vagina is then
sutured, and the uterus is fixed (round and sacrouterine
ligaments). The flow of the anastomosed vessels can be
verified by ultrasound or fluxometry (19,20).
Immunosuppression
Immunosuppressive therapy is continued until birth, when
a cesarean section is performed and the allograft uterus is
removed. For that reason, the complications that this therapy
may cause for fetal development must be clarified. The only
information on the safety of new drugs during pregnancy and
lactation is from experimental and preclinical animal studies
because experimental trials on pregnant or lactating mothers
are prohibited. In the absence of controlled studies, negative
reports have predominantly stemmed from pharmacovigi-
lance, case reports and small case series (21). Table 1 shows the
protocols used for immunosuppressive therapy in human
uterine transplantation, involving induction and maintenance.
According to a systematic review of pregnancy in liver and
kidney transplantation recipients (22), approximately 75% of
all pregnant women who underwent liver or kidney trans-
plantation had live births; this result may have been due to
the special care provided to such patients by transplantation
centers. Major congenital malformations were observed in
approximately 3% of all transplanted pregnant women, a
rate similar to that in the non-transplant population. There-
fore, the majority of pregnancies in transplantation recipients
are safe and uncomplicated. The safety of immunosuppres-
sant drug use during pregnancy in transplanted women
according to the Food and Drug Administration (FDA) clas-
sification is shown in Table 2.
’ DISCUSSION
A significant body of global knowledge on solid organ
transplantation has now been acquired and validated,
Table 1 - Immunosuppressant therapy (induction, maintenance and rejection treatment) in human uterine transplantation studies.
Reference Immunosuppression Scheme
Induction Maintenance Rejection Treatment
Fageeh W. et al., 2002 (11) Cyclosporine 6 h prior to








Erman Akar M. et al., 2013 (12) Anti-thymocyte globulin
and 1 mg prednisolone.
TAC*, MMF** and prednisolone
for the first 12 months.
Then discontinued MMF and
replaced with azathioprine.
Doses of prednisone and
azathioprine
were adjusted.
Bra¨nnstro¨m M. et al., 2014 (19) 1 g MMF, 500 mg
methylprednisolone
and anti-thymocyte globulin.
TAC, MMF and oral
glucocorticosteroids
once daily on the day of surgery
and during the first 4 postoperative
days.
Treated with corticosteroids.
Bra¨nnstro¨m M. et al., 2015 (13) IV anti-thymocyte globulin
just before surgery and 12 h
later and 500 mg
methylprednisolone.
TAC and MMF during the
first 6 months.
Withdrawal of MMF after 6 months
and addition of azathioprine and
prednisolone.
Treated with corticosteroids.
Johannesson L. et al., 2015 (23) IV anti-thymocyte just before
surgery and 12 h later and
500 mg methylprednisolone.
TAC and MMF during the
first 10 months post-surgery.
Azathioprine instead of MMF after
10 months to avoid the potentially
teratogenic effects of MMF.
Five milligrams daily of
prednisolone and corticosteroids
or dose increments of TAC.
*TAC = tacrolimus,
**MMF = mycophenolate mofetil
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establishing fertile grounds for the development of new
surgical procedures. Better surgical technology and better
understanding of immunosuppressive therapy, preventing
severe adverse side effects, are factors contributing to this
improvement.
Although only few cases of successful uterine transplanta-
tion have been reported, these cases represent a huge
advance in the field of reproductive medicine, allowing
pregnancy in patients with no other alternative.
This treatment belongs to a new category of transplanta-
tion surgeries that aim to improve patients’ quality of life,
alongside procedures such as face or hand transplantation
(23). The World Health Organization guarantees the right of
women to procreate, and uterine transplantation is recom-
mended for women who have uterine agenesis or a rudi-
mentary uterus or who have undergone hysterectomy due to
cervical, endometrial or ovary neoplasm; leiomyoma; or
hemorrhage complications during delivery. Despite initial
concern about the teratogenic effects of immunosuppression,
the strategy implemented in the Swedish study was suc-
cessful, so this strategy should be followed by other trans-
plantation centers. In that study, the uterus was preserved
post-partum, and immunosuppressive therapy was continued
to attempt a second gestation in certain patients. Furthermore,
the birth of healthy babies from organ-transplanted women
has confirmed the efficacy and safety of certain immunosup-
pressive therapy during gestation following uterus transplan-
tation (13,18,23,24).
The most successful cases of uterine transplantation
involving live donors were reported in Gothenburg, Sweden
(13). At the time of writing, no large series of transplantations
using uteruses from deceased donors has been performed, and
to date, none of the cases reported has resulted in a live birth.
The lack of success with deceased donors could be related to
the donors’ previous conditions, such as vasoactive drug use
and elevated serum levels of inflammatory mediators, as well
as to the type of preservative solution used to store the organ
and the duration of cold ischemia. This situation can be
improved via a better understanding of how to maintain the
deceased donor and by both the development of a better
preservative solution and the improvement of perfusion
pumps. Therefore, the viability and potential success of
transplantation performed with uteruses from deceased
donors still need to be assessed.
Early tests of uterine transplantation have been much
more promising than the early phases of transplantation of
other solid organs, such as the kidney, heart and liver.
However, the first uterine transplantation surgeries per-
formed required a long time in surgery. In the future,
following the completion of a larger number of cases and
with the improvement of surgical techniques, this time will
be reduced, as has been observed in the evolution of the
transplantation of other organs.
In sum, uterine transplantation is a new and viable
therapeutic option for patients with uterus-related infertility
who wish to have a child, as long as this transplantation is
performed at centers of expertise that specialize in human
reproduction and transplantation techniques and related
skills.
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